CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Lipid modification - primary and secondary CVD prevention - Management
When should I offer lipid modification therapy for secondary prevention of cardiovascular disease?
- Offer lipid modification therapy to all adults with cardiovascular disease (e.g. people with a past or current history of myocardial infarction, angina, stroke, transient ischaemic attack, or peripheral arterial disease).
Basis for recommendation
- These recommendations are based on those issued by the National Institute for Health and Clinical Excellence (NICE) [NICE, 2008a] which were based on an earlier NICE Technology Appraisal of statins for the prevention of cardiovascular events [NICE, 2006].
- NICE concluded that statins are clinically effective and cost effective for people with cardiovascular disease (CVD) [NICE, 2006]:
- There is good evidence that statins reduce all-cause mortality, CVD mortality, coronary heart disease mortality, fatal myocardial infarction, and coronary revascularization, when compared with placebo, in people with coronary heart disease.
- Sensitivity analysis undertaken by NICE indicates a high probability (greater than 85%) that statin therapy is cost effective for all people with a history of cardiovascular disease.
© NHS Institute for Innovation and Improvement